Site is Being Upgraded

Glycolipid-based Lifespan extension therapy:  α-galactosylceramide (α-GalCer), a synthetic glycolipid, increases life span via up-regulation of its target gene BubR1, 18/May/2018, 1.29 pm

Amylin comes to the rescue of autoimmune diabetes: Amylin-based adjunct therapy for autoimmune diabetes (TIDM): Amylin, a 37-residue peptide hormone, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 18/May/2018, 11.29 am
May 18, 2018
A glycolipid-based therapy for glucose homeostasis and TIIDM: α-Galactosylceramide (α-gal-cer), a synthetic glycolipid, increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 18/May/2018, 2.03 pm
May 18, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Glycolipid-based Lifespan extension therapy:  α-galactosylceramide (α-GalCer), a synthetic glycolipid, increases life span via up-regulation of its target gene BubR1


What is known? 

α-galactosylceramide (α-GalCer) has been shown to protect against autoimmune diseases, including TIDM. However, the exact mechanism of action is far from clear.


From Research Findings to Therapeutic Opportunity: 

This study suggests, for the first time, that α-galactosylceramide (α-GalCer)by increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

Figure 1. α-galactosylceramide (α-GalCer) may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. The chemical structure of α-galactosylceramide (α-GalCer).

 

 

 

 

 

 

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “α-galactosylceramide (α-GalCer) or its analogues, either alone or in combination with other drugs,” may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How α-galactosylceramide (α-GalCer) increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Glycolipid-based Lifespan extension therapy:  α-galactosylceramide (α-GalCer), a synthetic glycolipid, increases life span via up-regulation of its target gene BubR1, 18/May/2018, 1.29 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.